Scott,
Thanks for the clear and understandable presentation of TRIBY as a value or growth play and the dynamics of market psychology. Your reasoning is tough to refute. I would like to add just a few possibilities that could skew things a bit and, for me, justifies a hold and wait position.
1. The Europeans are grossly under proportioned as stockholders and could add a real boost once (if) they discover their own. If you think the PR's been lousey over here, it's been worse in Europe, ex Ireland.
2. The forces for change within and without the FDA to speed nontoxic processes, may finally have grown enough to have an impact.
3. Even considering recent gains in micro/small cap indexes, they are still significantly lagging in the longest bull run in history. A little catch up ball is possible.
4. I think the testing sector as a whole will be getting more attention as the baby boomers are reaching the " I don't know, I just don't feel so hot" years and what I admit is old news may get polished up anew. 5. I'm not as down on the new PR firm as most. I think they can make a difference. In today's information age, two strong stories and Roanan oozing Celtic charm on CNBC could easily overcome the perception that this is currently neither a good growth or value play. Look at some of the crap selling for $6-$8 today because its been polished up nice.
In any event, I've enjoyed and have learned from your last two postings, Thanks, Bill |
